| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bullying biosimilars: cheaper drugs stymied in USA
|
The Lancet Gastroenterology & Hepatology,
|
|
2018
|
3 |
6 |
p. 371
|
artikel
|
| 2 |
Claude Bernard: no ordinary man
|
Burki, Talha Khan
|
|
2018
|
3 |
6 |
p. 381
|
artikel
|
| 3 |
Correction to Lancet Gastroenterol Hepatol 2018; 3: 337–48
|
|
|
2018
|
3 |
6 |
p. e3
|
artikel
|
| 4 |
Delineating the global challenges of hepatitis B virus infection
|
Dusheiko, Geoffrey
|
|
2018
|
3 |
6 |
p. 372-373
|
artikel
|
| 5 |
Diffusion-weighted MRI in inflammatory bowel disease
|
Pouillon, Lieven
|
|
2018
|
3 |
6 |
p. 433-443
|
artikel
|
| 6 |
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
|
|
|
2018
|
3 |
6 |
p. 383-403
|
artikel
|
| 7 |
Infliximab biosimilar CT-P13 for inflammatory bowel disease
|
Bonovas, Stefanos
|
|
2018
|
3 |
6 |
p. 373-375
|
artikel
|
| 8 |
Is there anybody out there?
|
VanHouten, Melissa Adams
|
|
2018
|
3 |
6 |
p. 382
|
artikel
|
| 9 |
Research in brief
|
Baker, Holly
|
|
2018
|
3 |
6 |
p. 380
|
artikel
|
| 10 |
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial
|
Reni, Michele
|
|
2018
|
3 |
6 |
p. 413-423
|
artikel
|
| 11 |
San Francisco's ambitious plan to eliminate hepatitis C
|
Nelson, Roxanne
|
|
2018
|
3 |
6 |
p. 378
|
artikel
|
| 12 |
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
|
Strik, Anne S
|
|
2018
|
3 |
6 |
p. 404-412
|
artikel
|
| 13 |
Shifting the treatment model for resectable pancreatic cancer
|
Ko, Andrew H
|
|
2018
|
3 |
6 |
p. 375-376
|
artikel
|
| 14 |
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination
|
Meyer, Tim
|
|
2018
|
3 |
6 |
p. 376-377
|
artikel
|
| 15 |
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
|
Kudo, Masatoshi
|
|
2018
|
3 |
6 |
p. 424-432
|
artikel
|
| 16 |
The International Liver Congress 2018
|
Brierley, Rob
|
|
2018
|
3 |
6 |
p. 379
|
artikel
|
| 17 |
White oesophagus
|
Blouhos, Konstantinos
|
|
2018
|
3 |
6 |
p. 444
|
artikel
|
Tijdschrift beschrijving